Navigation Links
Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
Date:4/7/2009

Enhanced Functionality Empowers Users to Take Full Control of the Entire Clinical Trial Registration Process - from Assessment to Results Disclosure - while Adhering to Changing Regulatory Requirements; Two Top-Ten Pharmaceutical Companies Choose PharmaCM to Manage Their Clinical Trial Registration and Results Disclosure Processes

NEW YORK, April 7 /PRNewswire/ -- Intrasphere Technologies (http://www.intrasphere.com), a leading services firm that provides business-focused services and solutions to Life Sciences organizations, today announced the release of version 1.5 of the company's PharmaCM Clinical Trial Registration (CTR) solution powered by Microsoft Office SharePoint Server 2007. New features include: enhanced validation for Basic Results registration, bulk imports for Adverse Events, enhanced location management and user-controlled workflows, among others. Intrasphere also announced that two large global pharmaceutical organizations have signed on to use PharmaCM CTR 1.5 to manage their clinical trial registration and results disclosure processes.

The enhanced features of the Clinical Trial Registration solution are a next-generation set of tools that are developed to simplify what is currently a complex, paper-based method of managing clinical trial registration. The latest features of version 1.5 include:

-- Enhanced validation: for clinical trials Basic Results that help to reduce issues and feedback from ClinicalTrials.gov.

-- Adverse Events bulk import: to streamline the upload of Adverse Event data to ClinicalTrials.gov.

-- Location management: to easily identify and manage site differences.

-- Enhanced workflow: to accommodate complex decision trees and SOP's; to provide increased control to better govern actions and next ste
'/>"/>

SOURCE Intrasphere Technologies
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
2. Fina Technologies Names Spotfire Founder Christopher Ahlberg to Board of Directors
3. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
4. VisualSonics to Sell Mauna Kea Technologies Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market
5. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
6. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
7. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
8. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
9. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
10. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
11. RainDance Technologies Reviews Opportunities for Growth at Cowen Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... CIRENCESTER, England , September 29, 2014 /PRNewswire/ ... tighter margins and greater competition to transform network ... brand   ProLabs , ... infrastructure products, announced today the findings of their ... Optical Communications (ECOC) with top optical communications professionals ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
(Date:9/29/2014)... , Sept. 29, 2014 CytRx ... research and development company specializing in oncology, today ... (FDA) has granted multiple Orphan Drug Designations for ... indications: glioblastoma multiforme (GBM), small cell lung cancer ... of the widely-used chemotherapeutic agent, doxorubicin. ...
Breaking Biology Technology:SQI Diagnostics Announces New Chairman of Board of Directors 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... Therapeutics,Inc. (Nasdaq: IMRX ), a biopharmaceutical company ... financial,results for the first quarter ended March 31, ... Highlights:, -- Entered into agreement with Abbott ... obligation under non-recourse promissory note issued in connection ...
... Spain, May 15 Forest,Laboratories, Inc. (NYSE: ... a webcast to discuss aclidinium bromide clinical and ... Annual Congress.,The webcast, which will include a slide ... May 21, 2008 at 9:30am New York time, ...
... Care Advisory Panel reacts to CMS final rule; ... identifies challenges, recommends ... Industries, Inc. and,the International Expert Wound Care Advisory ... to Improve Pressure,Ulcer Prevention and Treatment: Implications of ...
Cached Biology Technology:ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 2ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 3ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 4ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 5ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 6ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 7Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 2International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper 3
(Date:9/29/2014)... ago when the supercontinent of Pangea was starting to break ... different kinds of reptiles called phytosaurs and rauisuchids were at ... believed the two top predators didn,t interact much as the ... the land. But those ideas are changing, thanks largely to ... published online in September in the German journal ...
(Date:9/29/2014)... has significant anti-tumour activity in patients with advanced ... disease has progressed after chemotherapy, according to phase ... in Madrid, Spain. , "Reports of lung ... interest because these mutations may be associated with ... lead author Dr David Planchard, pulmonary oncologist at ...
(Date:9/29/2014)... 2014 NXT-ID, Inc. (Nasdaq: NXTD ... authentication company focused on the growing mobile commerce market, ... been named the Company,s Vice-President and Chief Financial Officer ... as Chief Financial Officer. Mr. Pereira will continue to ... a Director. Mr. Miceli, age 56, has ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3NXT-ID, Inc. Names Vice-President and Chief Financial Officer 2NXT-ID, Inc. Names Vice-President and Chief Financial Officer 3
... Chalmers University of Technology have built a very simple ... directions, even though the antenna is smaller than the ... online journal Nature Communications this week ... very low concentrations of gases or biomolecules. A ...
... 2011 The Translational Genomics Research Institute (TGen) is ... $3.5 million grant from Susan G. Komen for the ... form of this cancer that disproportionately affects African-Americans. ... of physicians and scientists called Promise Grants, multi-million dollar, ...
... of Utah researchers have discovered a new class of compounds ... and inhibit it from infecting cells an early step ... virus. Development and laboratory testing of the potential new ... a study set for online publication by Friday in the ...
Cached Biology News:Bimetallic nanoantenna separates colors of light 2TGen breast cancer research benefits from $3.5 million Komen award 2TGen breast cancer research benefits from $3.5 million Komen award 3Targeting HIV's sugar coating 2Targeting HIV's sugar coating 3
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Luminex 100 IS System is a compact ... that integrates lasers, optics, fluidics, a controller, advanced ... This powerful, compact lab analysis system includes the ... Also, it has a DMF file at the ...
... gradient system is ideal for routine binary separations. ... sensitive Adept CE 4201 UV-Visible variable wavelength detector. ... provided by the two highly accurate and ... 4100 solvent delivery pumps., Chromatograms may be plotted ...
... Hep G2 cells were cultured in Minimum Essential ... at the log phase of growth. In ... forms, cells were fixed in acetone-methanol. The ... adhesive coated slide, with each wells surface specifically ...
Biology Products: